{"type":"trials","record":{"id":41495,"source_id":"clinicaltrials-gov","external_id":"NCT05456828","title":"A Study of ASKG712 in Patients With Neovascular Age-Related Macular Degeneration","brief_summary":"The purpose of the Phase 1/2a study is comprised of single ascending-dose component (Part 1), multiple ascending-dose component (Part 2) and multiple-dose extension component (Part 3) to evaluate the safety, tolerability, pharmacokinetics, and efficacy of ASKG712 in patients with neovascular age-related macular degeneration (nAMD).","overall_status":"Completed","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Visara, Inc.","enrollment":56,"countries":["China"],"start_date":"2023-02-10","completion_date":"2025-11-03","last_update_date":"2026-06-12","source_url":"https://clinicaltrials.gov/study/NCT05456828","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 80 Years","comparator":null,"organization":"Visara, Inc.","interventions":["ASKG712"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Incidence of ocular adverse events (AEs) of the study eyes — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks","Incidence of non-ocular adverse events (AEs) — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks","Area under the concentration time curve (AUC) — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks","Maximum plasma concentration (Cmax) — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks","Anti-Drug Antibody — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks","Mean change from baseline in best corrected visual acuity (BCVA) as measured by Early Treatment of Diabetic Retinopathy…","Mean change from baseline in central subfield thickness (CST) of macula measured by optical coherence tomography (OCT)…","Mean change from baseline in choroidal neovascularization area measured by fundus angiography — Part 1: 6 weeks; Part 2…"],"design_description":"NA · SEQUENTIAL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Neovascular Age-related Macular Degeneration","ASKG712"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05456828","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-02-10 to 2025-11-03","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years to 80 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.822Z","intervention":["ASKG712"],"participants":56,"study_design":"NA · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Incidence of ocular adverse events (AEs) of the study eyes — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks","Incidence of non-ocular adverse events (AEs) — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: up to 36 weeks","Area under the concentration time curve (AUC) — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks","Maximum plasma concentration (Cmax) — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks","Anti-Drug Antibody — Part 1: 6 weeks; Part 2: 20 weeks; Part 3: 20 weeks","Mean change from baseline in best corrected visual acuity (BCVA) as measured by Early Treatment of Diabetic Retinopathy…","Mean change from baseline in central subfield thickness (CST) of macula measured by optical coherence tomography (OCT)…","Mean change from baseline in choroidal neovascularization area measured by fundus angiography — Part 1: 6 weeks; Part 2…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41495","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}